|
|
Article: FDA Clears SQI's Automated SQiDworks Diagnostics Platform and IgXPLEX Rheumatoid Arthritis Assay for Sale in the United States.
- Article from:
- Biotech Week
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks™ Diagnostics Platform and its multiplexed IgXPLEX™ rheumatoid arthritis (RA) assay for marketing in the United States (see also Arthritis).
The SQiDworks Diagnostics Platform and its IgXPLEX RA assay provide clinical laboratories with the ability to simultaneously measure multiple biomarkers in a single test that delivers accurate patient results in less time, using less labour.
"Early and accurate diagnosis is ...